Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Inhaled ETD002 in Healthy Subjects
NCT04488705Phase 1Completed
- Sponsor
- Enterprise Therapeutics
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GDC-6988 in cystic fibrosis (CF) (4 arms), sponsored by Enterprise Therapeutics. Primary endpoints: Number of participants reporting one or more treatment emergent adverse event, Number of participants who discontinue due to an adverse event and 4 more. Started Aug 2020; status: completed.
02
Drugs
GDC-6988
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04488705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488705.